Stocks
Arcutis Biotherapeutics Financial Statements (ARQT) |
||||||||||
| Arcutis Biotherapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.03.2020 | 16.02.2021 | 22.02.2022 | 28.02.2023 | 27.02.2024 | 14.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 3.69 | 59.6 | 106.4 | |||
| Operating Income, bln rub | -43.1 | -136.6 | -206.5 | -301.6 | -241.1 | -196.5 | ||||
| EBITDA, bln rub | ? | -42.9 | -136.5 | -206.5 | -295.8 | -239.2 | -189.9 | |||
| Net profit, bln rub | ? | -42.0 | -135.7 | -205.9 | -321.3 | -262.1 | -217.4 | |||
| OCF, bln rub | ? | -42.8 | -113.0 | -174.6 | -257.7 | -247.1 | -198.3 | |||
| CAPEX, bln rub | ? | 0.295 | 0.321 | 0.995 | 23.3 | 0.428 | 0.346 | |||
| FCF, bln rub | ? | -43.1 | -113.4 | -175.6 | -281.0 | -247.5 | -198.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 43.1 | 136.6 | 206.5 | 304.6 | 294.6 | 295.2 | ||||
| Cost of production, bln rub | 0.195 | 0.455 | 0.763 | 0.754 | 6.12 | 7.66 | ||||
| R&D, bln rub | 36.5 | 115.3 | 145.6 | 182.4 | 110.6 | 98.4 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 15.7 | 29.7 | 30.2 | ||||
| Assets, bln rub | 107.0 | 298.3 | 408.2 | 449.3 | 341.4 | 478.5 | ||||
| Net Assets, bln rub | ? | -65.0 | 270.6 | 297.7 | 209.6 | 88.7 | 224.9 | |||
| Debt, bln rub | 0.307 | 4.96 | 77.6 | 202.5 | 205.9 | 206.7 | ||||
| Cash, bln rub | 101.3 | 284.4 | 387.1 | 409.6 | 272.8 | 404.5 | ||||
| Net debt, bln rub | -101.0 | -279.5 | -309.5 | -207.0 | -66.9 | -197.7 | ||||
| Ordinary share price, rub | 28.1 | 20.7 | 14.8 | 3.23 | 2.21 | |||||
| Number of ordinary shares, mln | 38.1 | 35.7 | 49.4 | 55.0 | 69.3 | 111.0 | ||||
| Market cap, bln rub | 0 | 1 003 | 1 025 | 814 | 224 | 245 | ||||
| EV, bln rub | ? | -101 | 724 | 715 | 607 | 157 | 48 | |||
| Book value, bln rub | -65 | 271 | 298 | 202 | 82 | 219 | ||||
| EPS, rub | ? | -1.10 | -3.80 | -4.17 | -5.84 | -3.78 | -1.96 | |||
| FCF/share, rub | -1.13 | -3.18 | -3.55 | -5.11 | -3.57 | -1.79 | ||||
| BV/share, rub | -1.71 | 7.59 | 6.03 | 3.68 | 1.19 | 1.97 | ||||
| EBITDA margin, % | ? | -8 025% | -401.3% | -178.5% | ||||||
| Net margin, % | ? | -8 716% | -439.8% | -204.4% | ||||||
| FCF yield, % | ? | -11.3% | -17.1% | -34.5% | -110.6% | -80.9% | ||||
| ROE, % | ? | 64.6% | -50.1% | -69.2% | -153.3% | -295.6% | -96.7% | |||
| ROA, % | ? | -39.2% | -45.5% | -50.4% | -71.5% | -76.8% | -45.4% | |||
| P/E | ? | 0.00 | -7.40 | -4.98 | -2.54 | -0.85 | -1.13 | |||
| P/FCF | 0.00 | -8.85 | -5.83 | -2.90 | -0.90 | -1.24 | ||||
| P/S | ? | 221.0 | 3.76 | 2.31 | ||||||
| P/BV | ? | 0.00 | 3.71 | 3.44 | 4.02 | 2.72 | 1.12 | |||
| EV/EBITDA | ? | 2.35 | -5.30 | -3.46 | -2.05 | -0.66 | -0.25 | |||
| Debt/EBITDA | 2.35 | 2.05 | 1.50 | 0.70 | 0.28 | 1.04 | ||||
| R&D/CAPEX, % | 12 380% | 35 921% | 14 629% | 783.6% | 25 835% | 28 431% | ||||
| CAPEX/Revenue, % | 631.7% | 0.72% | 0.33% | |||||||
| Arcutis Biotherapeutics shareholders | ||||||||||
